UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
| Date of Report (Date of Earliest Event Reported): | June 30, 2010 |
ADVENTRX Pharmaceuticals, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)
| Delaware | 001-32157 | 84-1318182 |
| _____________________ (State or other jurisdiction | _____________ (Commission | ______________ (I.R.S. Employer |
| of incorporation) | File Number) | Identification No.) |
| 6725 Mesa Ridge Road, Suite 100, San Diego, California | 92121 | |
| _________________________________ (Address of principal executive offices) | ___________ (Zip Code) |
| Registrant’s telephone number, including area code: | 858-552-0866 |
Not Applicable
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.07 Submission of Matters to a Vote of Security Holders.
The annual meeting of stockholders of ADVENTRX Pharmaceuticals, Inc. (the “Company”) was held on June 30, 2010. The final voting results on each of the matters submitted to a vote of the Company’s stockholders were as follows:
| 1. | The stockholders elected each of the five nominees to the Company’s board of directors, each to serve until the Company’s 2011 annual meeting of stockholders and until their respective successors are elected and qualified, as follows: |
| Nominee | For | Against | Abstain | Broker Non-Votes | ||||||||||||
| Michael M. Goldberg | 1,413,058 | 157,645 | 20,924 | 7,853,454 | ||||||||||||
| Odysseas D. Kostas | 1,411,768 | 159,953 | 19,907 | 7,853,453 | ||||||||||||
| Jack Lief | 1,409,903 | 161,308 | 20,416 | 7,853,454 | ||||||||||||
| Mark J. Pykett | 1,353,926 | 216,758 | 20,944 | 7,853,453 | ||||||||||||
| Eric K. Rowinsky | 1,411,289 | 161,177 | 19,161 | 7,853,454 | ||||||||||||
| 2. | The stockholders ratified the appointment of J.H. Cohn LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2010 as follows: |
| For | Against | Abstain | ||||||
| 8,945,881 | 410,635 | 88,565 | ||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ADVENTRX Pharmaceuticals, Inc. | ||||
| July 2, 2010 | By: | /s/ Patrick Keran | ||
| Name: Patrick Keran | ||||
| Title: President and Chief Operating Officer | ||||